141 related articles for article (PubMed ID: 33711148)
1. Scoring of tumour response after neoadjuvant therapy in resected pancreatic cancer: systematic review.
van Roessel S; Janssen BV; Soer EC; Fariña Sarasqueta A; Verbeke CS; Luchini C; Brosens LAA; Verheij J; Besselink MG
Br J Surg; 2021 Mar; 108(2):119-127. PubMed ID: 33711148
[TBL] [Abstract][Full Text] [Related]
2. Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: international interobserver study (ISGPP-1).
Janssen BV; van Roessel S; van Dieren S; de Boer O; Adsay V; Basturk O; Brosens L; Campbell F; Chatterjee D; Chou A; Doglioni C; Esposito I; Feakins R; Fuchs TL; Fukushima N; Gill AJ; Hong SM; Hruban RH; Kaplan J; Krasinkas A; Luchini C; Shi C; Singhi A; Thompson E; Velthuysen MF; Besselink MG; Verheij J; Wang H; Verbeke C; Fariña A;
Br J Surg; 2022 Dec; 110(1):67-75. PubMed ID: 36331867
[TBL] [Abstract][Full Text] [Related]
3. Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems.
Matsuda Y; Ohkubo S; Nakano-Narusawa Y; Fukumura Y; Hirabayashi K; Yamaguchi H; Sahara Y; Kawanishi A; Takahashi S; Arai T; Kojima M; Mino-Kenudson M
Sci Rep; 2020 Oct; 10(1):18278. PubMed ID: 33106543
[TBL] [Abstract][Full Text] [Related]
4. Critical issues in pathologic evaluation of pancreatic ductal adenocarcinoma resected after neoadjuvant treatment: a narrative review.
Taherian M; Wang H
Chin Clin Oncol; 2022 Jun; 11(3):21. PubMed ID: 35726190
[TBL] [Abstract][Full Text] [Related]
5. Regression grading in neoadjuvant treated pancreatic cancer: an interobserver study.
N Kalimuthu S; Serra S; Dhani N; Hafezi-Bakhtiari S; Szentgyorgyi E; Vajpeyi R; Chetty R
J Clin Pathol; 2017 Mar; 70(3):237-243. PubMed ID: 27681847
[TBL] [Abstract][Full Text] [Related]
6. Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy.
Janssen BV; Tutucu F; van Roessel S; Adsay V; Basturk O; Campbell F; Doglioni C; Esposito I; Feakins R; Fukushima N; Gill AJ; Hruban RH; Kaplan J; Koerkamp BG; Hong SM; Krasinskas A; Luchini C; Offerhaus J; Sarasqueta AF; Shi C; Singhi A; Stoop TF; Soer EC; Thompson E; van Tienhoven G; Velthuysen MF; Wilmink JW; Besselink MG; Brosens LAA; Wang H; Verbeke CS; Verheij J;
Mod Pathol; 2021 Jan; 34(1):4-12. PubMed ID: 33041332
[TBL] [Abstract][Full Text] [Related]
7. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
[TBL] [Abstract][Full Text] [Related]
8. Pancreatoduodenectomy following neoadjuvant chemoradiation therapy in uncinate process pancreatic cancer.
Kang CM; Choi JY; Seong JS; Song SY; Lee WJ; Kim MJ; Chung JB
Pancreas; 2012 Apr; 41(3):467-73. PubMed ID: 22158068
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiation.
Neyaz A; Tabb ES; Shih A; Zhao Q; Shroff S; Taylor MS; Rickelt S; Wo JY; Fernandez-Del Castillo C; Qadan M; Hong TS; Lillemoe KD; Ting DT; Ferrone CR; Deshpande V
Histopathology; 2020 Jul; 77(1):35-45. PubMed ID: 32031712
[TBL] [Abstract][Full Text] [Related]
10. Microscopic size measurements in post-neoadjuvant therapy resections of pancreatic ductal adenocarcinoma (PDAC) predict patient outcomes.
Zhang ML; Kem M; Rodrigues C; Sandini M; Ciprani D; Hank T; Kunitoki K; Qadan M; Ferrone C; Lillemoe K; Fernández-Del Castillo C; Mino-Kenudson M
Histopathology; 2020 Jul; 77(1):144-155. PubMed ID: 31965618
[TBL] [Abstract][Full Text] [Related]
11. Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival.
Lee SM; Katz MH; Liu L; Sundar M; Wang H; Varadhachary GR; Wolff RA; Lee JE; Maitra A; Fleming JB; Rashid A; Wang H
Am J Surg Pathol; 2016 Dec; 40(12):1653-1660. PubMed ID: 27631521
[TBL] [Abstract][Full Text] [Related]
12. The spectrum of histopathological changes encountered in pancreatectomy specimens after neoadjuvant chemoradiation, including subtle and less-well-recognised changes.
Kalimuthu SN; Serra S; Dhani N; Chetty R
J Clin Pathol; 2016 Jun; 69(6):463-71. PubMed ID: 26915370
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant treatment of surgically resectable pancreatic ductal adenocarcinoma.
Tesfaye AA; Philip PA
Clin Adv Hematol Oncol; 2019 Jan; 17(1):54-63. PubMed ID: 30843899
[TBL] [Abstract][Full Text] [Related]
14. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
15. The Role of Radiation Therapy for Pancreatic Cancer in the Adjuvant and Neoadjuvant Settings.
Badiyan SN; Molitoris JK; Chuong MD; Regine WF; Kaiser A
Surg Oncol Clin N Am; 2017 Jul; 26(3):431-453. PubMed ID: 28576181
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes.
McGuigan A; Kelly P; Turkington RC; Jones C; Coleman HG; McCain RS
World J Gastroenterol; 2018 Nov; 24(43):4846-4861. PubMed ID: 30487695
[TBL] [Abstract][Full Text] [Related]
17. Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations From the Pancreatobiliary Pathology Society.
Wang H; Chetty R; Hosseini M; Allende DS; Esposito I; Matsuda Y; Deshpande V; Shi J; Dhall D; Jang KT; Kim GE; Luchini C; Graham RP; Reid MD; Basturk O; Hruban RH; Krasinskas A; Klimstra DS; Adsay V;
Am J Surg Pathol; 2022 Jun; 46(6):754-764. PubMed ID: 34889852
[TBL] [Abstract][Full Text] [Related]
18. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
[TBL] [Abstract][Full Text] [Related]
19. Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy.
Pai RK; Pai RK
Mod Pathol; 2018 Jan; 31(1):4-23. PubMed ID: 28776577
[TBL] [Abstract][Full Text] [Related]
20. Prolonged Neoadjuvant Therapy for Locally Advanced Pancreatic Cancer.
Eguchi H; Yamada D; Iwagami Y; Gotoh K; Kawamoto K; Wada H; Asaoka T; Noda T; Takeda Y; Tanemura M; Sakai D; Satoh T; Kudo T; Isohashi F; Mori M; Doki Y
Dig Surg; 2018; 35(1):70-76. PubMed ID: 28482348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
